Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
In a phase 2 trial, researchers randomly assigned 204 patients with diabetic gastroparesis (DG) (mean age, 55.1 years; 32.3% men) into a double blind, placebo-controlled study for 28 days. Patients were enlisted to take two daily injections of relamorelin-131 10 mcg (RM-131; Rhythm) before an evening meal (n=67), RM-131 10 mcg before breakfast and an evening meal (n=68) or placebo (n=69). Patients' daily symptoms were recorded on a 0-10 scale, and a gastric emptying breath test (GEBT) was performed at baseline and on day 28.
http://www.diabetesincontrol.com/ar...atment-for-symptoms-of-diabetic-gastroparesis
http://www.diabetesincontrol.com/ar...atment-for-symptoms-of-diabetic-gastroparesis